Necrobiosis Lipoidica

oPatientPlus articles are written by UK doctors and are based on research evidence, UK and European Guidelines. They are designed for health professionals to use, so you may find the language more technical than the condition leaflets.

Necrobiosis lipoidica is an inflammatory skin disorder characterised by irregularly shaped, callous lesions with reddish-brown pigmentation and central atrophy. It was originally described in conjunction with diabetes - in 1929, by Oppenheim who coined the name dermatitis atrophicans lipoidica diabetica and, in 1932, by Urbach who called it necrobiosis lipoidica diabetica. As it occurs in the absence of diabetes as well, it is now known as necrobiosis lipoidica, a term applied to all cases, whether occurring in those with diabetes or not.

The pathology is collagen degeneration with granulomatous response, associated with thickened blood vessels and fat deposition. The underlying cause is unknown but is believed to involve microangiopathy.[1] 

Save time & improve your PDP on Patient.co.uk

  • Notes Add notes to any clinical page and create a reflective diary
  • Track Automatically track and log every page you have viewed
  • Print Print and export a summary to use in your appraisal
Click to find out more »

It is a rare skin condition. Whilst there is a high prevalence of diabetes mellitus in patients with necrobiosis lipoidica (one third of cases have diabetes, and two thirds have glucose tolerance abnormalities), the reported prevalence of necrobiosis lipoidica in patients with diabetes is 1-2%. It most commonly presents in the 30s but can present at any age, including infancy. It tends to appear earlier in those with diabetes than in others: in one study, approximately 2% of young people with diabetes (aged up to 22 years) had a necrobiosis lipoidica lesion compared with none of the control subjects.[3] It is three times as common in women as it is in men. Non-diabetic familial clustering of necrobiosis lipoidica does occur but extremely rarely.

Smoking is more prevalent in patients with diabetes with necrobiosis lipoidica than in those without it, as are diabetic complications (retinopathy and nephropathy), although the presence of necrobiosis lipoidica does not correlate with diabetic control.

Necrobiosis lipoidica Wiki Commons
  • Shiny patches slowly enlarge over months or years. They are initially a reddish brown and 1-3 mm in diameter but progress to yellow and become depressed and atrophic plaques.
  • The most common site is the pretibial area but they can occur on the face, scalp, trunk and upper arms where they are less likely to be correctly diagnosed.
  • There is often no pain (due to associated neuropathy) but it can be very painful.
  • Trauma produces ulceration.
  • Köbner's phenomenon may be demonstrated, in which lesions occur in areas of trauma. (This phenomenon is more typically associated with psoriasis and lichen planus.)

Usually the appearance is fairly typical but variations can be difficult to diagnose. Consider as a cause of atypical leg ulcers in diabetic patients.[4]

  • Superficial annular lesions may look like granuloma annulare. However, granuloma annulare do not exhibit the typical yellow fatty appearance of necrobiosis lipoidica plaques.
  • Yellow, fatty lesions may resemble xanthoma.
  • Sarcoidosis can appear very similar, even on histology.
  • Erythema nodosum. These lesions do not ulcerate.
  • Rheumatoid nodules are similar histologically but tend to be raised rather than atrophic. Ulcerated necrobiotic areas have been described in rheumatoid arthritis.
  • Varicose eczema produces a scaly rash and is usually near the malleoli.

If the patient is not known to have diabetes this must be checked. Biopsy of the lesion may be helpful but be aware of poor wound healing.

Management is impaired by lack of understanding of the aetiology of the condition. No treatment to date is completely effective and, whilst numerous treatments have been tried, none has proven effectiveness based on controlled trials.

  • Trauma should be avoided, and strategies for prevention of ulcers employed. Wound care for established ulcers is as for other diabetic ulcers.
  • Potent topical steroids are usually considered first-line treatment. This may reduce inflammation but it does not benefit burned-out lesions and may aggravate atrophy, so careful monitoring for this is required. Intralesional injections of steroids are also sometimes helpful, but increase the risk of ulceration.
  • Immunomodulating drugs have also been used, with varying levels of success, to treat necrobiosis lipoidica:
    • Ciclosporin[6]
    • Topical tacrolimus[7]
    • Anti-tumour necrosis factor alpha (anti-TNF-α) therapies[8]
    Studies demonstrate spontaneous healing of necrobiosis lipoidica following pancreas and kidney transplantation and the immunosuppressive regime is though to have played a significant role in this.[9][10] 
  • Antiplatelet treatment seems logical but controlled trials have had different results. Aspirin and dipyridamole have been used. Pentoxifylline decreases blood viscosity and increases fibrinolysis and erythrocyte deformity and it may be helpful. Ticlopidine and perilesional injections of heparin have been used in uncontrolled trials.
  • Excision and grafting are occasionally used but poor healing and recurrence are common.
  • Phototherapy. Photodynamic therapy has been used, as have topical retinoids and topical psoralens with ultraviolet A (PUVA).
  • Laser treatment has been used to stabilise lesions and reduce erythema and telangiectasias.

The lesions do not heal well and are usually considered a chronic, relapsing condition. They are known to remit spontaneously and even resolve. The most common complication is ulceration, but occasionally squamous cell carcinoma can arise in areas of long-standing necrobiosis lipoidica.[1][11]

Further reading & references

  1. Reid SD, Ladizinski B, Lee K, et al; Update on necrobiosis lipoidica: a review of etiology, diagnosis, and treatment options. J Am Acad Dermatol. 2013 Nov;69(5):783-91. doi: 10.1016/j.jaad.2013.05.034. Epub 2013 Aug 19.
  2. Grillo E, Rodriguez-Munoz D, Gonzalez-Garcia A, et al; Necrobiosis lipoidica. Aust Fam Physician. 2014 Mar;43(3):129-30.
  3. Pavlovic MD, Milenkovic T, Dinic M, et al; The prevalence of cutaneous manifestations in young patients with type 1 diabetes. Diabetes Care. 2007 Aug;30(8):1964-7. Epub 2007 May 22.
  4. Gottrup F, Karlsmark T; Leg ulcers: uncommon presentations. Clin Dermatol. 2005 Nov-Dec;23(6):601-11.
  5. Erfurt-Berge C, Seitz AT, Rehse C, et al; Update on clinical and laboratory features in necrobiosis lipoidica: a retrospective multicentre study of 52 patients. Eur J Dermatol. 2012 Nov-Dec;22(6):770-5. doi: 10.1684/ejd.2012.1839.
  6. Stanway A, Rademaker M, Newman P; Healing of severe ulcerative necrobiosis lipoidica with cyclosporin. Australas J Dermatol. 2004 May;45(2):119-22.
  7. Rallis E, Korfitis C, Gregoriou S, et al; Assigning new roles to topical tacrolimus. Expert Opin Investig Drugs. 2007 Aug;16(8):1267-76.
  8. Suarez-Amor O, Perez-Bustillo A, Ruiz-Gonzalez I, et al; Necrobiosis lipoidica therapy with biologicals: an ulcerated case responding to etanercept and a review of the literature. Dermatology. 2010;221(2):117-21. doi: 10.1159/000314694. Epub 2010 Jun 25.
  9. Gullo D, Latina A, Tomaselli L, et al; Healing of chronic necrobiosis lipoidica lesions in a type 1 diabetic patient after pancreas-kidney transplantation: a case report. J Endocrinol Invest. 2007 Mar;30(3):259-62.
  10. Souza AD, El-Azhary RA, Gibson LE; Does pancreas transplant in diabetic patients affect the evolution of necrobiosis Int J Dermatol. 2009 Sep;48(9):964-70.
  11. Lim C, Tschuchnigg M, Lim J; Squamous cell carcinoma arising in an area of long-standing necrobiosis lipoidica. J Cutan Pathol. 2006 Aug;33(8):581-3.

Disclaimer: This article is for information only and should not be used for the diagnosis or treatment of medical conditions. EMIS has used all reasonable care in compiling the information but make no warranty as to its accuracy. Consult a doctor or other health care professional for diagnosis and treatment of medical conditions. For details see our conditions.

Original Author:
Dr Chloe Borton
Current Version:
Peer Reviewer:
Dr Hannah Gronow
Last Checked:
21/05/2014
Document ID:
3001 (v24)
© EMIS